Masimo vs Zhonghong Pulin Medical Products: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Masimo Corporation (MASI)

Q3 202622 Jun – 22 Jul 2026

▲3

Masimo acquired by Danaher; FDA win and Apple patent ruling shape outlook

Danaher completes $9.9B acquisition of Masimo Danaher finished buying Masimo for $9.9 billion, and Masimo's stock was delisted from NASDAQ. Shareholders got a premium. Masimo now runs as a standalone unit inside Danaher's diagnostics business, so MASI no longer trades as a separate public stock.
This is the single biggest event that changes MASI's status and price permanently.
FDA clears AI opioid detection on Radius VSM Masimo won FDA clearance for an AI feature that detects opioid-related breathing problems on its wearable monitor. This expands Masimo's product usefulness in hospitals and could drive more sales of its monitoring systems, supporting the value Danaher paid.
New product approval directly boosts Masimo's growth potential and justifies the acquisition.
Apple patent verdict upheld, but trade secret damages denied A judge kept a $634 million patent win for Masimo against Apple, but rejected Masimo's claim for up to $3.1 billion in trade secret damages. Masimo is appealing. The mixed outcome leaves legal uncertainty but preserves a major cash award.
This legal battle affects Masimo's finances and future royalty income, a key swing factor.
Danaher Q2 results show Masimo integration on track Danaher's second-quarter results were solid, with Masimo contributing and helping offset higher debt costs from the acquisition. This suggests Masimo's business is performing as expected inside Danaher, supporting the deal's long-term value.
Confirms the acquisition is adding value and not dragging on Danaher, which matters for Masimo's future funding and growth.

July 202622 Jun – 22 Jul 2026

▲3

Masimo acquired by Danaher; FDA win and Apple patent ruling shape outlook

Danaher completes $9.9B acquisition of Masimo Danaher finished buying Masimo for $9.9 billion, and Masimo's stock was delisted from NASDAQ. Shareholders got a premium. Masimo now runs as a standalone unit inside Danaher's diagnostics business, so MASI no longer trades as a separate public stock.
This is the single biggest event that changes MASI's status and price permanently.
FDA clears AI opioid detection on Radius VSM Masimo won FDA clearance for an AI feature that detects opioid-related breathing problems on its wearable monitor. This expands Masimo's product usefulness in hospitals and could drive more sales of its monitoring systems, supporting the value Danaher paid.
New product approval directly boosts Masimo's growth potential and justifies the acquisition.
Apple patent verdict upheld, but trade secret damages denied A judge kept a $634 million patent win for Masimo against Apple, but rejected Masimo's claim for up to $3.1 billion in trade secret damages. Masimo is appealing. The mixed outcome leaves legal uncertainty but preserves a major cash award.
This legal battle affects Masimo's finances and future royalty income, a key swing factor.
Danaher Q2 results show Masimo integration on track Danaher's second-quarter results were solid, with Masimo contributing and helping offset higher debt costs from the acquisition. This suggests Masimo's business is performing as expected inside Danaher, supporting the deal's long-term value.
Confirms the acquisition is adding value and not dragging on Danaher, which matters for Masimo's future funding and growth.

Latest22 Jun – 22 Jul 2026

▲3

Masimo acquired by Danaher; FDA win and Apple patent ruling shape outlook

Danaher completes $9.9B acquisition of Masimo Danaher finished buying Masimo for $9.9 billion, and Masimo's stock was delisted from NASDAQ. Shareholders got a premium. Masimo now runs as a standalone unit inside Danaher's diagnostics business, so MASI no longer trades as a separate public stock.
This is the single biggest event that changes MASI's status and price permanently.
FDA clears AI opioid detection on Radius VSM Masimo won FDA clearance for an AI feature that detects opioid-related breathing problems on its wearable monitor. This expands Masimo's product usefulness in hospitals and could drive more sales of its monitoring systems, supporting the value Danaher paid.
New product approval directly boosts Masimo's growth potential and justifies the acquisition.
Apple patent verdict upheld, but trade secret damages denied A judge kept a $634 million patent win for Masimo against Apple, but rejected Masimo's claim for up to $3.1 billion in trade secret damages. Masimo is appealing. The mixed outcome leaves legal uncertainty but preserves a major cash award.
This legal battle affects Masimo's finances and future royalty income, a key swing factor.
Danaher Q2 results show Masimo integration on track Danaher's second-quarter results were solid, with Masimo contributing and helping offset higher debt costs from the acquisition. This suggests Masimo's business is performing as expected inside Danaher, supporting the deal's long-term value.
Confirms the acquisition is adding value and not dragging on Danaher, which matters for Masimo's future funding and growth.

Zhonghong Pulin Medical Products Co. Ltd. (300981.CS)

Q3 202628 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

August 202628 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

Latest28 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.